Aclipse Therapeutics develops novel and highly differentiated therapeutics to treat life-threatening and severe diseases. Our approach leverages the wealth of human genomic, proteomic and biomarker data to develop disease-modifying drug candidates.
Aclipse Therapeutics focuses on molecular pathways that regulate cellular stress, protein misfolding and inflammation. Our focus is on neurodegenerative and gastrointestinal diseases that are strongly impacted by these molecular pathways. We believe that developing precision medicine approaches will allow for the identification of potential drug responders and thereby improve patient outcomes.
M102 is a potential disease-modifying therapeutic candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig’s disease. ALS is a fatal, progressive neurodegenerative disease affecting voluntary muscles. ALS is also a complex disease with multiple disease pathomechanisms. M102 takes a broad mechanistic approach to treat ALS with dual activation of NRF2 and HSF1 pathways affecting multiple ALS pathomechanisms including oxidative stress, neuro-inflammation, mitochondrial dysfunction, protein misfolding and Endoplasmic Reticulum stress, aberrant RNA metabolism, axonpathy, and dysregulated vesicle transport. We are also developing precision medicine approaches to allow for the potential stratification of ALS patients.
M107 is the first potential disease-modifying drug for the treatment of gastroparesis, a serious gastrointestinal disease affecting stomach nerves and muscles resulting in stomach paralysis or delayed emptying. M107 seeks to treat the underlying pathology of gastroparesis by switching pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages and shutting down inflammation in the stomach.